Microbix Biosystems Inc.

265 Watline Avenue, Mississauga, Ontario L4Z 1P3
Tel: 905-361-8910 Fax: 905-361-8911

News Release

MICROBIX TO PRESENT AT 2015 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE

TORONTO, April 29, 2015 – Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, today announced that its CFO, Charles Wallace, will present an update of the Company's business at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 5, 2015 at 3:00 p.m. Eastern Time.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About Microbix Biosystems Inc.

Microbix specializes in the research and development of biological solutions, including human health products for vaccine, therapeutic and diagnostic global markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a global customer base. Microbix' pipeline of innovative technologies and products includes LumiSort™, a semen sexing technology for the livestock industries; Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots; and VIRUSMAX®, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. Established in 1988, Microbix is based in Mississauga, Ontario and is listed on the Toronto Stock Exchange under the trading symbol 'MBX'.

Forward-Looking Information

This news release includes "forward-looking information", as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, the risks associated with development projects, operations in foreign jurisdictions, risks associated with engineering and construction generally, risks associated with production including control over costs, quality, quantity and timeliness of delivery of products, foreign currency and exchange rate risk, and risks of raising capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgment as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit www.sedar.com for recent Microbix Biosystems Inc. filings.

For further information, please visit www.microbix.com or contact:

Company Contacts:
Vaughn C. Embro-Pantalony
CEO
(905) 361-8910 x 350
vaughn.embro-pantalony@microbix.com

Charles Wallace
CFO
(905) 361-8910 x 255
charles.wallace@microbix.com

Investor Relations:
Stephen Kilmer
(647) 872-4849
stephen.kilmer@microbix.com